Aptevo Therapeutics, Inc. APVO 深 沪
已收盘 02-06 16:00:00 美东时间
6.70
+0.690
+11.48%
华盛通- 最 高6.84
- 今 开6.06
- 成交量 5.10万股
- 最 低 6.06
- 昨 收 6.01
- 总市值 668.55万
- 52周最高 1439.964
- 市盈率 静 --
- 换手率 5.12%
- 52周最低 5.94
- 委 比 -84.62%
- 总股本 99.78万
- 历史最高 68020444.80
- 量 比 0.72
- 振 幅 12.98%
- 历史最低 5.94
- 每 手 1
- 风险率 377.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aptevo Therapeutics President, CEO Marvin White To Retire, Effective April 1, Transitioning To Executive Chair; COO Jeff Lamothe Appointed President, CEO
Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today
02-03 21:14
APVO stock has given up its prior gain. Aptevo Therapeutics shares were trading higher after the company entered into a $60 million equity line of credit agreement with Yorkville Advisors Global.
APVO stock has given up its prior gain. Aptevo Therapeutics shares were trading...
01-09 23:02
Aptevo Therapeutics shares are trading higher after the company entered into a $60 million equity line of credit agreement with Yorkville Advisors Global.
Aptevo Therapeutics shares are trading higher after the company entered into a ...
01-09 21:07
Aptevo Therapeutics Implements 1-for-18 Reverse Stock Split
Aptevo Therapeutics ( ($APVO) ) has shared an update. On July 24, 2025, Aptevo ...
2025-12-30 06:29
What's Going On With Aptevo Therapeutics Stock Today?
Shares of Aptevo Therapeutics are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.
2025-12-26 23:24
Aptevo Therapeutics shares are trading lower after the company announced a 1-for-18 reverse stock split.
Aptevo Therapeutics shares are trading lower after the company announced a 1-fo...
2025-12-26 21:07
Aptevo Therapeutics Announces Promising RAINIER Trial Results
Aptevo Therapeutics ( ($APVO) ) just unveiled an announcement. On December 9, 2...
2025-12-10 06:48
Aptevo Therapeutics Presents Preliminary Results From Ongoing Phase 1b/2 RAINIER Study Evaluating Mipletamig In Combination With AZA/VEN For Newly Diagnosed AML Patients, At ASH Annual Meeting
100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of
2025-12-09 21:12
Aptevo Therapeutics Q3 EPS $(2.23) Misses $(2.09) Estimate
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(2.23) per share which missed the analyst consensus estimate of $(2.09) by 6.7 percent. This is a 99.38 percent increase over losses of $(357.86) per share
2025-11-06 21:37
Market-Moving News for September 18th
INTC: 34% | Nvidia And Intel To Jointly Develop AI Infrastructure And Personal Computing Products, Nvidia To Invest $5B In Intel's Stock At $23.28 Per Share NVO: 7% | Novo Nordisk Announced Ozempic Reduces
2025-09-18 19:21
